Asunto(s)
Dolor Crónico/tratamiento farmacológico , Hipohidrosis/complicaciones , Dolor Intratable/tratamiento farmacológico , Risperidona/uso terapéutico , Antagonistas de la Serotonina/uso terapéutico , Biopsia , Dolor Crónico/etiología , Humanos , Hipohidrosis/patología , Masculino , Persona de Mediana Edad , Dolor Intratable/etiología , Piel/patología , Resultado del TratamientoAsunto(s)
Linfocitos B , Eritema/patología , Seudolinfoma/diagnóstico , Enfermedades de la Piel/diagnóstico , Anciano , Eritema/complicaciones , Humanos , Masculino , Seudolinfoma/complicaciones , Seudolinfoma/patología , Piel/patología , Enfermedades de la Piel/complicaciones , Enfermedades de la Piel/patologíaRESUMEN
Percutaneous peptide immunization (PPI) is a simple and noninvasive immunization approach to induce potent CTL responses by peptide delivery via skin with the stratum corneum removed. After such a barrier disruption in human skin, epidermal Langerhans cells, although functionally matured through the up-regulation of HLA expression and costimulatory molecules, were found to emigrate with a reduced number of dendrites. CD8(+) populations binding to MHC-peptide tetramers/pentamers and producing IFN-gamma appeared in the blood after PPI with HLA class I-restricted antigenic peptides. PPI with melanoma-associated peptides reduced the lesion size and suppressed further development of tumors in four of seven patients with advanced melanoma. These beneficial effects were accompanied by the generation of circulating CTLs with in vitro cytolytic activity and extensive infiltration of tetramer/pentamer-binding cells into regressing lesions. PPI elicited neither local nor systemic toxicity or autoimmunity, except for vitiligo, in patients with melanoma. Therefore, PPI represents a novel therapeutic intervention for cancer in the clinical setting.
Asunto(s)
Melanoma/inmunología , Melanoma/terapia , Péptidos/administración & dosificación , Péptidos/inmunología , Linfocitos T Citotóxicos/inmunología , Administración Cutánea , Adulto , Anciano , Antígenos de Neoplasias/inmunología , Movimiento Celular/inmunología , Epítopos de Linfocito T/inmunología , Estudios de Seguimiento , Humanos , Interferón gamma/biosíntesis , Interferón gamma/inmunología , Masculino , Melanoma/patología , Persona de Mediana Edad , Estadificación de NeoplasiasRESUMEN
Interactions between chemokines and chemokine receptors are involved in migration and invasion of lymphoma cells. We investigated expression profiles of CXCR3 and CCR4 by immunohistochemistry and flow cytometry, and their biologic behaviors by real-time horizontal chemotaxis assay in cutaneous T cell and NK/T-cell lymphomas (TCLs). Tumor cells in mycosis fungoides (MF) constantly expressed CXCR3 at the patch stage, and expressed CCR4 at the tumor stage and in the folliculotropic variant of MF. Neoplastic cells at the plaque stage expressed CXCR3 and/or CCR4. Sezary cells in the dermis and circulation were positive for CCR4. Epidermotropic atypical cells in pagetoid reticulosis expressed CXCR3. CD30 cells exclusively expressed CCR4 in anaplastic large-cell lymphoma, and CXCR3 and/or CCR4 in lymphomatoid papulosis. In CD8TCL and extranodal NK/TCL characterized by extensive epidermotropism, tumor cells were positive for CXCR3. These data demonstrated preferential expression of CXCR3 in epidermotropic tumor cells, and of CCR4 in dermis-based lymphomas. In chemotaxis assays, CCR4 tumor cells in MF and CXCR3 tumor cells in CD8TCL migrated to thymus and activation-regulated chemokine and inducible protein-10, respectively. Therefore, spatial and temporal interactions between chemokine receptors and their ligands seem to dictate recruitment and retention of lymphoma cells in the skin.